NM 505

Drug Profile

NM 505

Alternative Names: NM-505; Reformulated metformin - MicroBiome Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MicroBiome Therapeutics
  • Class Antihyperglycaemics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gastrointestinal microbiome modulators; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Type-2-diabetes-mellitus in USA (PO)
  • 09 Jun 2015 MicroBiome Therapeutics has patent protection for microbiome modulator-metformin combination NM 505 in USA
  • 09 Jun 2015 Efficacy and adverse events data from a clinical trial in Type-2 diabetes mellitus presented at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top